Anxiety disorders are widespread in the population and in general medical practice and have a pronounced negative impact on the quality of life and functioning of patients. Currently, the prerequisites for the diagnosis and treatment of anxiety disorders outside the psychiatric network are accumulating by therapists, general practitioners and other non-psychiatric doctors. A review of the most significant factors contributing to a wider diagnosis and treatment of anxiety disorders in general medical practice is given. This review presents modern ideas about the pathogenesis of anxiety disorders, substantiates the modern idea of their multifactorial nature, the contribution of genetic and epigenetic, psychological and social factors, outlines the concepts of the neurobiological basis of pathological anxiety based on neuroimaging studies. In the future, information is provided on the general manifestations of anxiety disorders, the main clusters of anxiety, the systematics of anxiety disorders according to ICD-10. Modern ideas about the diagnosis of anxiety disorders using both scales and a clinical approach are given, a detailed review of currently available diagnostic scales validated for clinical practice is presented. The main approaches to conducting a clinical conversation are also presented, recommendations are given for the most successful collection of information about the clinical condition of patients. At the end of the review, information is given on existing approaches to psychopharmacotherapy and psychotherapy of anxiety disorders. Taking into account pharmacological and clinical studies, the place of drugs tofisopam (an atypical allosteric modulator of GABA receptors) and buspirone (a partial agonist of serotonin 1A receptors) in the treatment of anxiety disorders in general medical practice has been argued.
25 October 2022 in Neurology, Neuropsychiatry, Psychosomatics
Depression is one of the most common mental disorders in neurological practice. Among other symptoms of depression, a symptom complex represented by apathy, anhedonia, and cognitive impairment plays an important role. This review presents the clinical characteristics of the symptoms described above and discusses modern neurochemical and neuroimaging concepts of their pathogenesis. The problem of pathogenetically substantiated therapy of depression with a predominance of apathy, anhedonia and cognitive impairment is discussed. Fundamental and clinical arguments are presented in favor of the high efficacy of vortioxetine in depression with a predominance of apathy, anhedonia, and cognitive impairment.
Introduction: Although neurosteroids have been relatively recently discovered, their significant role in the neurochemical processes and pathogenesis of a number of psychiatric and neurological disorders is now quite clear. First of all, it seems important to clarify the definition of the endogenous neurosteroids as a class of steroids, taking into account the variability of approaches to their description. Currently, neurosteroids include endogenous steroids synthesized in the central nervous system, gonads, or adrenal glands and interacting with GABAA, NMDA, and sigma-1 receptors. Neurosteroid biosynthesis: Biosynthesis of neurosteroids begins with rate-limiting reaction of TSPO binding cholesterol and transporting it into the mitochondria, where pregnenolone is synthesized following the cytochrome P450scc (CYP11A1) impact. Interaction with GABAА, NMDA and sigma-1 receptors: According to the experimental data, neurosteroids act as the most highly potent endogenous allosteric modulators of the GABA receptor; some types of neurosteroids (ALLO, DHEA, etc.) can produce a rapid anxiolytic and anticonvulsant effect. There is some experimental evidence for antipsychotic effects of some neurosteroids realized through NMDA receptors: intracerebral administration of ALLO to laboratory animals can prevent further appearance of motor agitation and other equivalents of psychosis after administration of high doses of amphetamines. It has also been proven in several studies on animal models that neurosteroids exhibit anxiolytic effects through sigma-1 receptors. Conclusion: The article describes the process of neurosteroidogenesis and the effect of neurosteroids on listed receptorsin accordance with already available scientific data. In addition, this paper describes the specific role of various neurosteroids in the development of mental illnesses, including anxiety disorders, depression, and schizophrenia Graphical Abstract
20 August 2023 in Meditsinskiy sovet = Medical Council
In the past decades, biofeedback has become a widely adopted non-pharmacological option in the management of a variety of somatic, neurological, and psychiatric conditions. The biofeedback method is based on the associations between one’s vegetative and mental functions; during a session with the device, information about the change in his/her condition over time is “returned” to the patient as accessible audial or visual stimuli. The efficacy of biofeedback treatment may primarily be attributed to improvements in the state of the patients based on establishing an individual model of his/her best psychophysiological state, enabling effective rehabilitation activities at a rate suitable for each patient along with ensuring better awareness of the patient of his/her body functions; such an intervention is stepwise and helps sustain the patient’s motivation for success, thus affecting the pathological condition. This review describes the historical prerequisites for the development of biofeedback techniques and the principal mechanisms of their action; a brief summary of studies looking at the efficacy of this method in various somatic, neurological, and psychiatric conditions is also provided. The presented data clearly indicate that the use of biofeedback results in a decreased medication load in patients suffering from conditions such as arterial hypertension, epilepsy, ADHD, chronic pain, anxiety disorders, autism etc. while there are practically no contraindications for this method, except for acute psychosis, photosensitive epilepsy, and severe cognitive impairment. In this connection, clinical implementation of biofeedback techniques should be intensified in a variety of conditions.
21 April 2023 in S.S. Korsakov Journal of Neurology and Psychiatry
Несмотря на доказанную значимость нейростероидов (НС) во многих физиологических процессах, их роль в патогенезе большинства психических заболеваний остается сравнительно малоизученной. В обзоре приводятся клинические данные о влиянии НС на формирование и терапию тревожного расстройства, депрессии, биполярного расстройства и шизофрении. В частности, указывается на неоднозначный характер воздействия НС на ГАМКА- и другие рецепторы. Особый интерес представляет анксиолитический и анксиогенный эффект некоторых НС, антидепрессивный эффект аллопрегнанолона в лечении послеродовой и других форм депрессий, природа кратко-и долгосрочных механизмов антидепрессивных эффектов НС разного вида. Также обсуждается на данный момент пока недоказанная гипотеза о влиянии изменения уровня НС на течение биполярного расстройства, проводится анализ научных данных о развитии шизофренической симптоматики в связи с изменением уровня НС в контексте позитивных и когнитивных симптомов.
14 August 2024 in Meditsinskiy sovet = Medical Council
Anxiety disorders are the most common group of mental disorders. The high prevalence of anxiety disorders and their negative impact on the functioning and quality of life of patients determines the need for timely diagnosis and therapy. The review presents data on the clinical manifestations of anxiety, as well as on the main forms of anxiety disorders according to current classifications of mental disorders. An analysis is conducted on the relationship between somatic and cognitive manifestations of anxiety, explaining the difficulties in diagnosing and treating patients with a predominance of somatic symptoms. Cognitive features specific to patients with anxiety disorders are described. Approaches to the diagnosis and differential diagnosis of anxiety disorders are provided, along with information on main psychometric scales. The importance of a clinical approach in diagnosing anxiety disorders is justified, and the role of para-clinical methods in establishing a diagnosis is described. According to recent consensus documents and clinical guidelines, the first-line therapies for anxiety disorders are cognitive-behavioral therapy and the use of selective serotonin reuptake inhibitors; the basics of both methods are described. Considering current research, both approaches have drawbacks, which necessitates the use of medication with an alternative mechanism of action. One such medication is the modern multimodal anxiolytic Aviandr, which has demonstrated high effectiveness and safety in treating patients with the most severe form of anxiety disorders – generalized anxiety disorder. The main points of the review are illustrated with a clinical example of the successful use of Aviandr in a patient with generalized anxiety disorder.